Viral Vector and Plasmid DNA Manufacturing Market Size
The Viral Vector and Plasmid DNA Manufacturing Market reached US$ 4.06 billion in 2025 and is expected to reach US$ 15.27 billion by 2033, growing at a CAGR of 14.2% during the forecast period 2026-2033.
Demand from institutes, associations, and foundations in North America is rising. Competitive rivalry intensifies with Cobra Biologics, MassBiologics, Thermo Fisher Scientific and others operating in the market.
The viral vector is referred to as the tool for delivering genetic material into cells. The modified viral vector is used as a viral vector in gene therapy. Plasmid DNA is a bacterial smaller, circular, and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.
As per DataM Intelligence, Viral Vector and Plasmid DNA Manufacturing Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Viral Vector and Plasmid DNA Manufacturing Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Viral Vector and Plasmid DNA Manufacturing Market in the United States and Canada produces the utmost share. Whereas the European Viral Vector and Plasmid DNA Manufacturing Market is projected to continue its presence globally during the period of 2024- 2031.
Market Scope
| Metrics | Details |
| Market CAGR | 14.2% |
| Segments Covered | By Product Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Viral Vector and Plasmid DNA Manufacturing Market Dynamics
The global viral vector and plasmid DNA manufacturing market growth is driven by several factors such as increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others.
Increasing demand for gene therapy and immunotherapy is expected to drive the global viral vector and plasmid DNA manufacturing market during the forecast period.
The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There are growing viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is an increase in the number of clinical studies examining the viral vectors' efficacy and safety and plasmid DNA.
Risk of mutagenesis associated with vector or plasmid treatments are likely to hinder the market growth
As genetic engineered viral vector and plasmid DNA are being used in various gene therapy and immunotherapy procedures. There is a risk of insertional mutagenesis associated with these genetic modified vectors and plasmids that can restrain the market growth and the high cost of gene treatments can also limit the growth of market.
Industry Analysis
The global viral vector and plasmid DNA manufacturing market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis, pricing analysis.
Viral Vector and Plasmid DNA Manufacturing Market Segmentation Analysis
The viral vector segment is expected to hold the largest market share in global viral vector and plasmid DNA manufacturing market
The global viral vector and plasmid DNA manufacturing market is segmented on the product type the plasmid DNA, viral vector, and non-viral vector. The viral vector segment accounts for the highest market growth due to the increasing penetration of the viral vectors for targeted delivery, efficient transduction, and controlled gene expression. There is an increase in the viral vectors' usage due to their efficiency in delivering genes into the target cells and protecting the new genes from degradation. Different types of viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus are used for transferring the nucleic acids into the genetic makeup of cells. Out of these viral vectors, adenovirus and retrovirus are widely used worldwide as these viral vectors have the integration ability with large transgenes and easy production at high titers.
Further, the market is also classified based on cancer, genetic disorder, infectious disease, and other diseases. The cancer segment accounts for the highest market share due to the higher usage of the viral vector and plasmid DNA for delivering the anti-cancer genes. Several biotechnology and pharmaceutical companies are examining the viral vectors or plasmid DNA encoding a therapeutic gene, often an immunomodulatory or suicide gene, in the various cancer gene therapy trials. Clinical studies have demonstrated that the injection of plasmid DNA encoding a cytokine gene has a significant antitumor effect. There are increasing research and development activities for gene therapies and other advanced cell therapies to treat various cancers. The increase in the approval of the viral vector and plasmid DNA-based therapies shall stimulate market growth. For instance, the lentiviral vector-based CAR-T cell therapies are approved for treating Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma.
Viral Vector and Plasmid DNA Manufacturing Market Geographical Share
North America region holds the largest market share in the global viral vector and plasmid DNA manufacturing market
By region, the global viral vector and plasmid DNA manufacturing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global viral vector and plasmid DNA manufacturing market and is expected to grow at the highest CAGR during the forecasted period due to the increasing number of clinical studies for evaluating the use of the viral vector and plasmid DNA for the treatment of the genetic disorders, cancer, and infectious diseases. The increase in the approval of advanced cell therapies shall stimulate market growth. There is growing research and development activities of gene therapies. Several companies, institutes, associations, and foundations raise the investment and funding to develop gene therapies. The growing initiatives by the Food and Drug Administration (FDA) for improving the regulatory support for cell and gene therapy shall boost the demand for viral vector and plasmid DNA manufacturing.
The Asia Pacific is expected to witness positive market growth due to the growing clinical transformation and industrialization of advanced therapies medicinal products, including gene therapy manufacturing. There is a presence of several companies manufacturing viral vector and plasmid DNA. Contract manufacturers are providing several services for viral vector and plasmid DNA manufacturing. There is growing adoption of advanced technologies for manufacturing viral vectors and plasmid DNA.
Viral Vector and Plasmid DNA Manufacturing Market Companies and Competitive Landscape
The global viral vector and plasmid DNA manufacturing market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.
Brammer Bio:
Overview: Brammer Bio is a contract development and manufacturing organization (CDMO) that develops and manufactures viral vector and helps biopharmaceutical companies to deliver breakthrough medicines in form of gene modified cell therapies to patients. Founded in 2013 and headquartered in Florida.
Product Portfolio:
Lipofectamine CRISPRMAX Cas9 Transfection Reagent: It is a 1st lipid nanoparticle optimized reagent for transfection use for CRISPR-Cas9 protein delivery. It is a cost effective, high throughput friendly alternate for electroporation.
Recent Developments
- March 2026 – FUJIFILM Diosynth Biotechnologies expands global viral vector capacity
Fujifilm Diosynth Biotechnologies is expanding viral vector and plasmid DNA production capabilities across its U.S. and Europe sites to support gene therapy pipelines and commercial launches. - March 2026 – Merck strengthens upstream and downstream plasmid DNA production technologies
Merck KGaA is advancing high-yield fermentation platforms and purification technologies to improve scalability and reduce production costs in plasmid DNA manufacturing. - February 2026 – Cobra Biologics and SIRION Biotech expand gene therapy CDMO services
Companies such as Cobra Biologics and SIRION Biotech are strengthening their AAV and lentiviral vector production pipelines, supporting increasing clinical trial demand. - February 2026 – Cell and Gene Therapy Catapult accelerates UK manufacturing ecosystem
Cell and Gene Therapy Catapult is expanding pilot-scale and commercial-scale manufacturing infrastructure to support UK-based gene therapy innovation and clinical translation. - January 2026 – FinVector Vision Therapies advances ocular gene therapy production
FinVector Vision Therapies is increasing production capacity for AAV-based ophthalmic gene therapies, reflecting rising demand for targeted rare disease treatments.
The global viral vector and plasmid DNA manufacturing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
